Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Benitec Biopharma (BNTC) Income from Continuing Operations (2019 - 2025)

Benitec Biopharma has reported Income from Continuing Operations over the past 7 years, most recently at 11987000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 11987000.0 for Q4 2025, down 773.69% from a year ago — trailing twelve months through Dec 2025 was 33901000.0 (down 121.11% YoY), and the annual figure for FY2025 was 38479000.0, down 78.26%.
  • Income from Continuing Operations reached 11987000.0 in Q4 2025 per BNTC's latest filing, down from 8792000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 1372000.0 in Q4 2024 and bottomed at 11987000.0 in Q4 2025.
  • Median Income from Continuing Operations over the past 5 years was 4688000.0 (2022), compared with a mean of 5334900.0.
  • The largest annual shift saw Income from Continuing Operations surged 80.21% in 2024 before it tumbled 773.69% in 2025.
  • Over 5 years, Income from Continuing Operations stood at 4846000.0 in 2021, then decreased by 15.95% to 5619000.0 in 2022, then decreased by 23.38% to 6933000.0 in 2023, then soared by 80.21% to 1372000.0 in 2024, then crashed by 773.69% to 11987000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for BNTC at 11987000.0 in Q4 2025, 8792000.0 in Q3 2025, and 8798000.0 in Q2 2025.